HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The gene for mesomelic dysplasia Kantaputra type is mapped to chromosome 2q24-q32.

Abstract
Mesomelic dysplasia Kantaputra type (MDK) (MIM *156232) is a new autosomal dominant skeletal dysplasia characterized by dwarfism, shortening of the forearms/lower-legs, carpal/tarsal synostosis, and dorsolateral foot deviation. We studied a Thai family in which 15 members in 3 generations were affected with MDK. With reference to the breakpoints of a balanced translocation [t(2;8)(q31;p21)] in patients from a previously reported Italian family with a skeletal dysplasia that appears similar to MDK, a linkage analysis was performed in the Thai family using 50 CA-repeat markers mapped to nearby regions (2q22-q34 and 8p24-p21) of the translocation breakpoints. The results clearly ruled out a linkage of MDK to marker loci at the 8p24-p21 region, whereas all nine affected members available for the study shared a haplotype at four loci (D2S2284, D2S326, D2S2188, and D2S2314) spanning about 22.7 cM in the 2q24-q32 region. The computer-assisted two-point linkage analysis revealed maximum logarithm of odds (lod) scores of 4.82, 4.21, 4.82, and 4.21 (theta = 0) at these loci, respectively. These data indicated that the MDK locus is in the vicinity of D2S2284 and D2S2188 loci that are most likely mapped to 2q24-q32.
AuthorsM Fujimoto, P N Kantaputra, S Ikegawa, Y Fukushima, S Sonta, M Matsuo, T Ishida, T Matsumoto, S Kondo, H Tomita, H X Deng, M D'urso, M M Rinaldi, V Ventruto, T Takagi, Y Nakamura, N Niikawa
JournalJournal of human genetics (J Hum Genet) Vol. 43 Issue 1 Pg. 32-6 ( 1998) ISSN: 1434-5161 [Print] England
PMID9609995 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Chromosome Mapping
  • Chromosomes, Human, Pair 2 (genetics)
  • Dwarfism (genetics)
  • Female
  • Genes, Dominant
  • Genetic Linkage
  • Haplotypes
  • Humans
  • Male
  • Pedigree

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: